Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
S Wang, SL Friedman - Science translational medicine, 2023 - science.org
Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …
that poses a global health threat because of its potential to progress to advanced fibrosis …
Diagnosis and management of autoimmune hepatitis
L Muratori, AW Lohse, M Lenzi - bmj, 2023 - bmj.com
Autoimmune hepatitis is an inflammatory disease of the liver of unknown cause that may
progress to liver cirrhosis and end stage liver failure if diagnosis is overlooked and treatment …
progress to liver cirrhosis and end stage liver failure if diagnosis is overlooked and treatment …
Multi-organ imaging demonstrates the heart-brain-liver axis in UK Biobank participants
Medical imaging provides numerous insights into the subclinical changes that precede
serious diseases such as heart disease and dementia. However, most imaging research …
serious diseases such as heart disease and dementia. However, most imaging research …
Diagnostic modalities of non-alcoholic fatty liver disease: from biochemical biomarkers to multi-omics non-invasive approaches
E Martinou, M Pericleous, I Stefanova, V Kaur… - Diagnostics, 2022 - mdpi.com
Non-Alcoholic Fatty Liver Disease (NAFLD) is currently the most common cause of chronic
liver disease worldwide, and its prevalence is increasing globally. NAFLD is a multifaceted …
liver disease worldwide, and its prevalence is increasing globally. NAFLD is a multifaceted …
[HTML][HTML] Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis
Background & Aims MRI-based corrected T1 (cT1) is a non-invasive method to grade the
severity of steatohepatitis and liver fibrosis. We aimed to identify genetic variants influencing …
severity of steatohepatitis and liver fibrosis. We aimed to identify genetic variants influencing …
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial
TG Simon, RM Wilechansky, S Stoyanova, A Grossman… - JAMA, 2024 - jamanetwork.com
Importance Aspirin may reduce severity of metabolic dysfunction–associated steatotic liver
disease (MASLD) and lower the incidence of end-stage liver disease and hepatocellular …
disease (MASLD) and lower the incidence of end-stage liver disease and hepatocellular …
Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis
Introduction Late stage clinical trials in non-alcoholic steatohepatitis (NASH) are currently
required by the FDA to use liver biopsy as a primary endpoint. The well-reported limitations …
required by the FDA to use liver biopsy as a primary endpoint. The well-reported limitations …
Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood‐based fibrosis markers in patients with chronic liver disease
ANA Jayaswal, C Levick, EA Selvaraj… - Liver …, 2020 - Wiley Online Library
Abstract Background & Aims Liver cT1, liver T1, transient elastography (TE) and blood‐
based biomarkers have independently been shown to predict clinical outcomes but have not …
based biomarkers have independently been shown to predict clinical outcomes but have not …
Multi‐parametric liver tissue characterization using MR fingerprinting: Simultaneous T1, T2, T2*, and fat fraction mapping
Purpose Quantitative T1, T2, T2*, and fat fraction (FF) maps are promising imaging
biomarkers for the assessment of liver disease, however these are usually acquired in …
biomarkers for the assessment of liver disease, however these are usually acquired in …
A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and …
Non-alcoholic steatohepatitis (NASH) is major health burden lacking effective
pharmacological therapies. Clinical trials enrol patients with histologically-defined NAFLD …
pharmacological therapies. Clinical trials enrol patients with histologically-defined NAFLD …